Screener
PTC Therapeutics PTCT EBITDA margin
EBITDA margin at other companies
Other financials
Where this comes from
Calculated from PTC Therapeutics’s reported figures.
Based on trailing twelve months.
The source filing: PTC Therapeutics’s 10-Q, filed May 7, 2026. Open the filing →
- Filed
- May 7, 2026, 4:32 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001070081-26-000012
FAQ
- What is PTC Therapeutics's EBITDA margin?
- PTC Therapeutics (PTCT) reported EBITDA margin of 7.3% in Q1 2026.
- How has PTC Therapeutics's EBITDA margin changed year-over-year?
- PTC Therapeutics's EBITDA margin decreased by 82.6% year-over-year, from 41.8% to 7.3%.
- What is the long-term trend for PTC Therapeutics's EBITDA margin?
- Over 5 years (2020 to 2025), PTC Therapeutics's EBITDA margin has grown at a -11.2% compound annual growth rate (CAGR), from -102% to 56.5%.
- What does EBITDA margin mean?
- EBITDA (earnings before interest, taxes, depreciation, and amortization) as a percentage of revenue, trailing twelve months. A proxy for cash operating profitability that strips out capital-structure and non-cash charges.
Ask your AI about PTC Therapeutics's ebitda margin.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude